| Trial ID: | L2386 |
| Source ID: | NCT00575874
|
| Associated Drug: |
Rivoglitazone Hcl
|
| Title: |
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
|
| Acronym: |
RAISE
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Rivoglitazone HCl|DRUG: rivoglitazone HCl|DRUG: rivoglitazone HCl|DRUG: pioglitazone HCl|DRUG: placebo
|
| Outcome Measures: |
Primary: Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo, 12 weeks | Secondary: Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Daiichi Sankyo Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
150
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-08
|
| Completion Date: |
2009-01
|
| Results First Posted: |
|
| Last Update Posted: |
2009-02-09
|
| Locations: |
Hong Kong, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00575874
|
